Incorporation of Ibrutinib Into Risk-Stratified Treatment for Post-Transplant Lymphoproliferative Disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial
Blood 2024 Apr 21;[EPub Ahead of Print], S Chaganti, S Maycock, G McIlroy, AE Jackson, R Bishop, S Johnson, E Kanfer, S Kassam, K Cwynarski, DJ Wrench, A Arumainathan, CP Fox, RJ Johnson, P McKay, S Paneesha, C Rowntree, C Balotis, GP Collins, AJ Davies, J Wright, S Burns, ADJ Laurence, K Wheatley, T MenneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.